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Abstract
Background: The "European Environment & Health Action Plan 2004–2010" originates from the concern of the
European Commission on the well-being of individuals and the general population. Through this plan, the Commission
has set the objectives to improve the information chain for a better understanding of the link between sources of
pollution and health effects, to better identify existing knowledge gaps, and improve policy making and communication
strategies. Human biomonitoring (HBM) has been included as one of the tools to achieve these objectives. As HBM
directly measures the amount of a chemical substance in a person's body, taking into account often poorly understood
processes such as bioaccumulation, excretion, metabolism and the integrative uptake variability through different
exposure pathways, HBM data are much more relevant for risk assessment than extrapolations from chemical
concentrations in soil, air, and water alone. However, HBM primarily is a stepping stone between environmental and
health data, and the final aim should be an integrated and holistic systematic risk assessment paradigm where HBM serves
as a pivotal point between environment and health, on the one hand leaning on environmental data to provide detailed
information on the sources and pathways of pollutants that enter the human body, and on the other hand clarifying new
and existing hypotheses on the relationship between environmental pollutants and the prevalence of diseases. With the
large amount of data that is being gathered in the different national survey projects, and which is expected to become
available in Europe in the near future through the expected European Pilot Project on HBM, a framework to optimize
data interpretation from such survey projects may greatly enhance the usefulness of HBM data for risk managers and
policy makers.
Results: This paper outlines an hierarchic approach, based on the stepwise formulation of 4 subsequent steps, that will
eventually lead to the formulation of a variety of policy relevant risk reduction options.
Conclusion: Although the usefulness of this approach still needs to be tested, and potential fine-tuning of the procedure
may be necessary, approaching the policy implications of HBM in an objective framework will prove to be essential.
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Introduction
The "European Environment & Health Action Plan 2004–
2010" originates from the concern of the European Com-
mission on the well-being of individuals and the general
population. While obviously our highly industrialized
European society provides many of its citizens with a very
high quality of life, there are also costs to this modern
society in terms of increased pollution, noise, climate
change and other stressors that may affect our every day
quality of life. Hence, it should be a constant goal of sci-
entists, risk managers and policy makers to maximize the
profits from our highly evolved society while minimizing
its health-related costs. Together with improving general
public health, there are also indirect yet large benefits in
terms of long-term economic growth and sustainable
development, since the indirect costs in productivity
losses due to illness or premature death may be substan-
tially larger than the cost for direct health care [1-3].
Hence, even while stringent environmental legislation, at
a local, national and European level, aims at minimizing
the negative effects of our modern society, there remains
a need to be on the outlook for existing, new and emerg-
ing stressors that may hamper the general population's
health. It is therefore essential to continuously monitor
our day-to-day environment and identify potential threats
as soon as possible, to evaluate the effect of mitigating
actions to deal with identified threats and to gather up-to-
date information on the state of the environment in gen-
eral [3,4].
Rather than merely looking at pollution sources, the Envi-
ronment and Health Action Plan 2004–2010 considered
a new approach to environmental policy making by revis-
ing and improving the health impact and risk assessment
strategies [5]. In this context, three main themes are iden-
tified that provide a roadmap to a cleaner, healthier and
better environment for its citizens. These themes are [1,2]:
1. Improving the information chain to understand the
links between sources of pollution and health effects;
2. Filling the knowledge gap by strengthening research
and addressing the emerging issues on environment and
health;
3. Reviewing policies and improving communication.
Within the context of this paper, especially the first theme
is of importance, with the perceived "need for the develop-
ment of a coherent approach to human biomonitoring in
Europe" presented specifically included in this theme as
Action 3. Also themes 2 and 3 have identified actions with
a direct relevance to the European Project on human bio-
monitoring, particularly through integrating European
environment and health research (Action 5) and review-
ing policies and improving risk communication. Human
biomonitoring (HBM) is defined as 'the measurement of
chemicals or their metabolites in human tissues or speci-
mens, such as blood or urine' [6]. Until recently, the tradi-
tional way of describing these relationships was by
estimating the concentration of chemicals in different
environmental compartments using empirical or mode-
ling efforts, taking into account human exposure esti-
mates to quantify the dose. However, due to both an
increase in analytical capacity and a change in social
awareness towards pollution exposure, there has been a
rapid increase in the development and application of
human biomonitoring (HBM) as a tool to evaluate expo-
sure (i.e. the use of human tissue or fluid samples to esti-
mate exposure). In many cases, HBM data have been
proven to be a valuable supplement, or have even sur-
passed, estimates of exposure based on environmental
measures [7-9]. HBM directly measures the amount of a
chemical substance or its metabolite in a person's body,
taking into account often poorly understood processes
such as bioaccumulation, excretion, metabolism and the
integrative uptake variability through different exposure
pathways, rather than each individual exposure source.
Hence, these data are much more relevant for risk assess-
ment than extrapolations from chemical concentrations
in soil, air, and water [9-11]. As was phrased by Stokstad
[12], "pollution gets personal" when HBM data are being
collected. Not only does this relate to a change of percep-
tion in the general public, it also integrates environmental
exposure in a way that is more likely to be consistent with
health effects, as the causative compounds have actually
entered the body and are still detectable [10]. However,
presenting HBM data without a proper context may lead
people to the understandable yet often incorrect assump-
tion that low levels of chemicals found in our tissues are
harmful, simply by their presence itself [9,13].
Within Action 3 of the Environment and Health Action
Plan 2004–2010, the need for integration of HBM data
with environmental and health data is specifically fore-
seen:
"Biomonitoring is not an automatic instrument, which can be
considered in isolation, but has to be integrated with environ-
mental monitoring, toxicological and eco-toxicological data and
especially with considerations related to analytical epidemiol-
ogy. [2]"
This statement highlights that human biomonitoring
(HBM) is not an island on itself, but should be considered
a stepping stone between environmental and health data
[11]. The final aim should be an integrated and holistic
systematic risk assessment paradigm where HBM serves as
a pivotal point between environment and health, on theEnvironmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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one hand leaning on environmental data to provide
detailed information on the sources and pathways of pol-
lutants that enter the human body, and on the other hand
clarifying new and existing hypotheses on the relationship
between environmental pollutants and the prevalence of
diseases or the occurrence and identification of disease
clusters [3,10,14].
HBM and the environment and health paradigm
Most examples on the use of HBM as a source of informa-
tion in the environment and health paradigm come from
small-scale, well documented research projects. In these
research projects, HBM data is considered a complemen-
tary source of information and data are gathered to pro-
vide more insight in the link between environment and
health, with a focus on hypothesis generation and testing.
Generally, the choice of biomarkers, matrix and identifi-
cation of the studied population are based on an a priori
research question, and choices are such that HBM data
offer an optimal source of information with regard to the
research question. This type of research project usually
cover only a limited geographical area, or a targeted sub-
group (pregnant women, children, etc.), a relatively lim-
ited number of participants and often address the rela-
tionship between environmental levels of contaminants
and the resulting human exposure. Well-known recent
examples in literature include the use of HBM to evaluate
the effect of fish eating or amalgam fillings on mercury
contamination [15-17], the effect of lead as an anti-knock-
ing agent in gasoline [18-20], or the effects of anti-smok-
ing laws on Cotinine levels [21-23]. Other research
projects address the links between the levels of pollutants
in the body and adverse health effects. Examples are the
relationship between methylmercury and neurobehavio-
ral deficits [24,25], between lead and intellectual perform-
ance of children [26,27], or between cadmium and effects
on the kidneys [28,29]. These research topics allow the
development of health based guidance values based on
levels of pollutants in the body.
On the other hand however, there are a number of large-
scale survey programs that have been developed inde-
pendent of any specific research questions, and are gener-
ally aimed at providing researchers and policy makers
with a broad picture of the pollutant load among the gen-
eral population. These survey projects often cover broad
geographical areas, include a wide variety of biomarkers,
and aim at providing periodical measurements of the
prevalence of exposure to environmental agents, with a
view to develop and evaluate policies that protect the
health of the general population. Examples of this type of
large-scale survey programs can be found in the German
Environmental Survey (GerES), the USA's Center for Dis-
ease Control (CDC) program on HBM, or the Flemish
Human Biomonitoring program. Often, these survey pro-
grams are associated with large-scale surveys on physical
and mental health, such as the NHANES study in the USA
[30] or KIGGS in Germany [31]. Table 1 gives some details
on some of the most extensive HBM survey programs cur-
rently in place.
The interpretation of HBM data in research projects is
often straightforward, since data were gathered specifi-
cally to provide information on a priori research question,
and the project was set up in such a way to maximize data
interpretability and usefulness. However, the same is not
necessarily true for HBM survey projects, since they gener-
ally provide a broad overview of pollutant exposure in the
general population, without focusing on predefined
research questions. However, within the vast amount of
data that is being gathered in the different national survey
projects, and which is expected to become available in
Europe in the near future (see further), a framework to
optimize data interpretation from such survey projects
may greatly enhance the usefulness of HBM data for risk
managers and policy makers. Evidently, survey and
research projects should as much as possible be linked,
where the research projects develop new biomarker tools,
insights and knowledge on the complex interactions
between HBM, environmental exposure and the resulting
health effects, which can later be tested at a larger scale in
survey projects.
Towards a European network on human 
biomonitoring
As was already introduced earlier, the Environment and
Health Action Plan 2004–2010 specifically addressed the
use of HBM to gain better understanding on the link
between environment and health issues, with the inten-
tion to develop a permanent harmonized European bio-
monitoring system [1,2,11]. Such a system will allow
better understanding of environment and health linkages
and long term health effects an will be used as a tool for
the development of further environmental policy. This
intention was later confirmed by the 2006 Environment
and Health Information Review and Implementation
Plan [11] and the opinion of the Scientific Committee on
Health and Environmental Risks [3].
As a first step towards the establishment of an EU network
on HBM, the European Commission launched the Expert
Team to Support Biomonitoring in Europe (ESBIO)
project (2004–2006), which consists of HBM experts
from several EU Member States, and Croatia. The four
main objectives of the ESBIO project were:
1. Development of a coordinated approach for biomoni-
toringEnvironmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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2. Elaboration how biomonitoring results can be inte-
grated most efficiently with environmental monitoring
and registered health data
3. Develop strategies to communicate biomonitoring
results to stakeholders
4. Elaboration of scenarios for the use of biomonitoring
results for policy making
ESBIO's work is directed towards the technical prepara-
tion of a European Pilot Project on Human Biomonitor-
ing, and regularly reports to the Implementation Group
on human biomonitoring, the European Commission
and the Consultative Forum on Environment and Health.
ESBIO's work is used as a basis by the Implementation
Group on human biomonitoring to formulate recom-
mendations to the Consultative Forum on the technical,
structural and organizational requirements of such a
European Pilot Project. Briefly, in the Implementation
Group's Third Recommendation to the Consultative
Forum on Environment and Health, it was suggested that
a European HBM network should focus on a limited
number of well-known, relatively easy to measure
biomarkers. Methylmercury in scalp hair, lead in blood,
cadmium in urine and cotinine in urine of both women
of childbearing age (22–50 years old) and their children,
age 6–11 [32]. For as many Member States as possible,
120 mother-child pairs per Member State will be asked to
donate the relevant blood, urine and hair samples. In the-
ory, this would thus mean having a study population of
3420 mother-child pairs, if all Member States choose to
participate. At this point in time, a call for tender has
indeed been issued by the European Commission within
the Seventh Framework Program (ENV2007.1.2.2.1:
European network on human biomonitoring), as yet no
details are available as to the granting of the project
[11,33]. It is within this context and framework of the
ESBIO project, as a prelude for the Pilot Project, that the
current document was developed.
In the following, we present a multi-step approach, which
consists of four consecutive phases that need to be
addressed in order to make better use of HBM survey data
and to improve interpretation of spatial and temporal var-
iation and potential health effects. The main advantage of
including such a multi-step approach in the study proto-
col from the start of the project onwards, is that it offers a
framework for the objective and impartial interpretation
of HBM data, and allows the interpretation process and
related decision making to be accessible to all participants
and the general public from the start of the study.
Step 1: Are there differences among biomarkers 
in time or space?
Mainly due to privacy and statistical reasons, HBM values
are most often not represented as individual values. Gen-
erally, there is at least some kind of aggregation of data.
This aggregation can take many forms, most commonly
based on age groups, gender, ethnicity, or, if spatial differ-
Table 1: Details on some HBM survey programs
# Compounds Time frame Number of participantsa
CDC [30] 116 1999–2000 7970
148 2001–2002 8945
GerES [15, 74] 17 1985–1986 2731
25 1990–1992 3966
32 1998 4645
61b 2003–2006 1244
FLEHS 6–9c 2002–2005 4300
ESBIOad [32] 4 2008–2010 6480
a The number of constituents may vary per compound. Numbers are given for cadmium as a proxy, because Cd measurements are easy and cheap 
and generally are measured in all participating constituents
bThe human biomonitoring program of the last GerES (GerES IV) included:
Lead, cadmium, mercury in blood
HCB, 3HCHs, DDE, PCB 138, 153, 180, 28, 52, 101 in blood
Nickel, mercury, arsenic, uranium, nicotine, cotinine, 6 metabolites of organophosphates, PCP and 9 other chlorophenols, 5 PAH metabolites, 5 
pyrethroid metabolites in urine.
In addition:
11 phthalate matabolites in urine
Bisphenol A in urine
Three additional PAH (like tetrol)
All in all 61 substances for human biomonitoring.
More substances in the additional programs on indoor air (VOC), dust (flame retardants), drinking water and biological indoor contamination 
(personal communication Becker and Kolossa, 2008)
c Depending on the age group considered
d The ESBIO program is a proposed program according to Action 3 of the Environment and Health Action plan 2004–2010Environmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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ences in biomarker values are of main interest, on a geo-
graphical level. Because it is of major importance that data
in the EU Pilot Project on HBM is available at a similar
scale as environment and health data in Europe, data will
preferably be aggregated at an appropriate geographical
level (for example according to the Nomenclature of Ter-
ritorial Units for Statistics (NUTS) classification), and it
will be possible to calculate basic descriptive statistics for
each geographical area [14]. Because differences in certain
factors, such as age, gender or smoking behavior can have
a significant effect on the outcome of HBM measure-
ments, the appropriate corrections will have to be made in
order to be able to adequately compare the different geo-
graphical areas.
Addressing this first step is mainly descriptive, and only
offers answers on which subgroups are most likely to be
exposed, and allows comparison of individual results to
the average exposure of the entire studied population.
Collecting individual biomarker values in this first step
also allows examination of the dose distribution among
the population and to identify the variability in biomar-
ker values (low and high doses). The distribution of
biomarker values is more informative than the average
values since it allows the identification the proportion of
high exposure groups in the population. However, this
first step does not necessarily provide any information on
risk or hazard of the biomarker studied, nor give informa-
tion on possible health effects, suspected sources of expo-
sure, or policy options to reduce exposure. The first step
aims at aggregating and assembling data in a geographical
framework, and offers constituents an idea of their pollut-
ant load and the distribution of pollutants among the
general population, compared to other regions, other peo-
ple, or compared to previous monitoring programs in the
same or different areas. Preferably, data will be presented
in the form of maps, immediately highlighting regional
differences. From a policy point of view, screening data
can identify unusually high exposure which can serve as
an early warning for unknown pollution sources or pol-
lutants, even if the health impact of exposure at a given
level cannot immediately be identified [11]. If HBM sur-
vey programs are repeated over time (see table 1), tempo-
ral evolutions can be derived. Not only does this provide
scientists with information on possible new and emerging
chemicals, but it can also provide information on the effi-
ciency of policy measures taken to anticipate a potential
threat [34]. For example, brominated flame retardants
have been shown to increase dramatically in the breast
milk of Swedish women over the last 30 years [35,36],
which in itself was considered reason enough to ban spe-
cific polybrominated diphenyl ethers.
Step 2: Are the observed differences reason for 
concern
It should be stressed that in the process of dealing with
step 1, there is generally no information on the toxicity or
potential hazard of substances included in the assess-
ment, unless in cases where clear dose-effect relationships
are known. In the example of brominated flame retard-
ants, Darnerud et al [36] concluded that there was only
very limited evidence of toxicity in humans was available,
and also epidemiological studies in occupationally
exposed workers found no consistent adverse effects
attributable to exposure to these chemicals. However, the
toxic potency of these chemicals was well demonstrated in
animal experiments and the strong temporal increase in
PBDE levels in the human population was considered a
strong enough message to trigger risk manager and policy
maker action.
Such strong and swift actions however are rare. Generally,
temporal or spatial increases are less obvious, and more
stringent rules need to be taken into account to assess the
hazard of biomarkers detected in different matrices.
Hence, after aggregation and appropriate correction of the
data, the appropriate HBM values (average, median, xth
percentiles (Px) such as P75, P90,...) are compared with
available benchmark or reference values in order to iden-
tify deviations. These values can be identified using a
number of different approaches:
Health-based legally binding standards: Currently, there
are no legally binding standards for internal exposure
concentrations due to environmental exposure to sub-
stances. However, occupational exposure research has led
to the development of e.g. "Threshold Limit Values" and
"Biological Exposure Indices (BEI)", health-based guid-
ance values for occupational exposure that can give an
indication on the maximum tolerable intake of toxicants.
BEI values for cadmium and lead were set at 5 μg Cd/L
blood or 5 μg Cd/g creatinine in urine, and 30 μg Pb/dL
in blood [37,38]. The European Union has set indicative
occupational exposure limits (IOELVs), which for nico-
tine was set at 0.5 mg/m3 for an 8 hour exposure period
[39], and the binding biological limit value for lead and
its organic compounds was set at 70 μg/100 mL blood,
with medical surveillance needed at individual levels
above 40 μg/100 mL blood, which was in 2002 lowered
to 30 μg/dL, although it was mentioned that exposure to
fertile women should be minimized [40]. However, these
exposure limits are based on occupational exposure, and
do not necessarily reflect adequate protection levels for
environmental exposure;
Threshold values: A number of international agencies
have developed guidelines, based on scientific research
and expert judgment, for compounds where adequateEnvironmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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consensus is available on the occurrence of health effects
at certain concentrations. For example, WHO has devel-
oped health based guidance values for among others lead
(10 μg/dL blood). Another good example of these values
are the German HBM-I and HBM-II data, which have been
established for a number of key pollutants (Table 2); The
Human Biomonitoring Commission (HBC) of the Ger-
man Federal Environment Agency recommends two dif-
ferent HBM values: HBM-I, the concentration of an
environmental toxin in a human biological material
below which there is no risk for adverse health effects, and
HBM-II, the concentration above which there is an
increased risk for adverse health effects in susceptible indi-
viduals of the general population and, consequently, an
urgent need to reduce exposure and to provide individual
biomedical advice;
Data from international literature: Based on internation-
ally reported data, it is possible to compare European bio-
monitoring data with data collected in other parts of the
world. For example, every two years the US-CDC pub-
lishes their 'National Report on Human Exposure to Envi-
ronmental Chemicals", providing a wealth of information
on the pollutant concentrations among different popula-
tion groups in the US [30]. The current report provides
HBM data on 148 chemicals, including Pb, Cd, Hg, and
cotinine, for more than 6000 inhabitants. Reference
ranges have been calculated from these substances, indi-
cating the values into which 95% of the investigated pop-
ulation fall. They can be used to identify subjects with an
increased level of exposure (in relation to background
exposure) to a given environmental toxin but they do not
represent health-related criteria for the evaluation of
human biological monitoring data. The data merely pro-
vide toxicologists and physicians with a reference range so
that they can determine whether or not people have been
exposed to higher levels of a particular chemical than are
found in the general population. These data will also help
scientists to plan and conduct research about exposure
routes and potential health effects [30]. Also, the German
Commission on Human Biological Monitoring develops
scientifically based criteria for the application and evalua-
tion of HBM data. From the repeated HBM programs (see
table 1), reference values, defined as the 95th percentile of
the distribution of concentrations of a specific compound
in a matrix of a reference population, are calculated as a
basis to identify individuals with an increased level of
exposure [41,42];
Historical data: In several European Member States, there
is already a wide variety of HBM data available from pre-
vious sampling programs, both research and survey pro-
grams. These data can serve as benchmark values,
especially to detect changes in toxicant concentrations
over time. For example, Germany has a history in HBM
programs, with the first German Environmental Survey
(GerES) reaching back as far as 1985–1986;
Calculated reference values: Based on the data obtained
in the Pilot Study, reference values and ranges can be cal-
culated for Europe as well as for the individual participat-
ing countries. HBM values from different countries or
geographical areas can be compared to these calculated
references. This will give an indication which areas have
pollutant concentrations above the European average,
and which are below this average. Apart from the average,
also the P90-value is very useful to identify areas with high
concentrations of a certain pollutant. The determination
of reference values for the whole of Europe is one of the
aims of the EU Pilot Project on HBM, which can be used
as benchmark values to identify areas with unusually high
exposure, or to detect future trends in pollutant [11].
There is generally no objective criterion to assess whether
"observed differences are a reason for concern" (step 2).
For a few chemicals, there are clear, internationally
accepted health based reference values (table 2), but for
the most part, there is no such benchmark available. As
argued earlier, simply detecting the presence of a chemical
in a biological matrix should not be confused with an
increased risk [4]. Hence, the establishment of an Expert
Panel is proposed as the most impartial way to identify,
evaluate, and rank biomarker data with respect to their
toxicity and concern for human health. This Expert Panel
Table 2: Examples of German HBM-I and HBM-II values for environmental pollutants
Matrix/Pollutant Target population HBM-I HBM-II
Lead in blood Females (18–45) and children < 12 100 μg/L 150 μg/L
Females > 45 and males 18 – 69 150 μg/L 250 μg/L
Mercury in blood Adults (18–69) 5 μg/L 15 μg/L
Cadmium in urine Adults (18–25) 1 μg/g creatinine 3 μg/g creatinine
Adults (26–69) 2 μg/g creatinine 5 μg/g creatinine
The Commission on Human Biological Monitoring of the German Federal Environmental Agency established in 1993 recommends two different 
HBM values: HBM I, the concentration of an environmental toxin in a human biological material below which there is no risk for adverse health 
effects, and HBM II, the concentration above which there is an increased risk for adverse health effects in susceptible individuals of the general 
populationEnvironmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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should be a multi-national group of scientists with expe-
rience or expertise in (a specific part of) the biomarker
under evaluation (e.g toxicologists, epidemiologists,
chemists, medical doctors). They should form an opinion
on the scientific relevance of the biomarker levels under
consideration, and should be able to differentiate, priori-
tize, and evaluate whether observed differences are a rea-
son for concern.
Step 3: Can potential (local) sources be 
identified?
Generally, both HBM research and survey projects gather
considerably more information than simply sampling
and analyzing biomarkers in a specified matrix. As already
mentioned earlier, HBM survey projects are often part of a
larger study on environment and health, and as in general,
participants are requested to fill in a more or less extensive
questionnaire. These questionnaires are constructed in
such a way that they provide researchers with detailed
information on the socio-economic background, food
preferences, hobbies, occupational exposure patterns, and
potential local sources of recent exposure. By careful anal-
ysis of the questionnaire data, researchers often are able to
pinpoint exposure sources to non-environmental factors
(e.g. lifestyle or work), local or individual environmental
factors (e.g. indoor air quality, food preferences) or gen-
eral environmental factors. Examples in literature on how
behavior may alter biomarker values include the observa-
tion that a diet rich in fish and amalgam fillings are gen-
erally the major source of MeHg exposure [15,16], how
consumption of free-range chicken eggs may often result
in substantially higher dioxin and dioxin-like PCB doses
than consumption of barn or cage eggs [43], or how
smoking restrictions have an impact on urinary cotinine
levels in non-smokers [44-46].
Moreover, to further refine the potential answers to this
third step, additional information such as pollutant con-
centrations measured in animals (e.g. ecosurveillance),
local environmental data from different environmental
compartments gathered through a variety of regional or
national monitoring networks with subsequent pollution
dispersal modeling, or industry pollution licenses may
prove highly valuable to provide more insight in local
sources of potential exposure. Ecosurveillance data from
the International Council for the Exploration of the Sea
(ICES) or OSPAR may provide additional information on
spatial patterns on mercury levels in seafood [47,48], or
pollution emission inventory databases like EPER (Euro-
pean Pollution Emission Register, [49] may provide high
quality and EU-wide information on potential sources of
contaminant emission and exposure.
Step 4: How to translate this information to 
policy makers and risk managers?
Generally, as an outcome of the process of going through
the three previous steps, there are three options on how
HBM data can be translated into advice for risk managers
or policy makers. A first option is that the higher exposure
in either time or space is due to (local) emission sources,
in which case policy makers should take measures to
develop and implement risk reduction strategies. Obvi-
ously, this cannot be done solely based on toxicological
information alone, and a multi-disciplinary weight-of-evi-
dence approach, in which toxicological, socio-economic,
political and stakeholder arguments are balanced in order
to optimize societal benefits (see further). One of the
most obvious examples of this option is the Stockholm
Convention on Persistent Organic Pollutants (POPs) (see
http://www.pops.int for more information). This ground-
breaking agreement aims at restricting or eliminating
POPs from production, and was heavily supported by bio-
monitoring data, in that many of these POPs were glo-
bally detected in blood, fat and breast milk [50-52]. Next
to driving new policy regulations, HBM can also be used
to evaluate the efficacity of existing regulations. Tobacco
laws aim to restrict exposure of the population to tobacco
smoke and hence reduce the health risks. Monitoring
cotinin in the urine of children, which is a tracer of expo-
sure to passive smoking, will allow to evaluate whether
implementation of these laws in different countries has
been successful in terms of reducing exposure to a vulner-
able population.
HBM will be especially relevant as a follow up tool for the
new ambitious REACH program regarding the implemen-
tation of a new chemicals policy in the EU, which aims at
a better protection of the environment and human health
in the EU. Human biomonitoring is a unique tool to eval-
uate the efficacy of the program, provided that validated
biomarkers for the chemicals under consideration are
available.
A second option is that higher exposure may be due to
lifestyle factors, in which case the best way forward is to
alter consumer behavior or lifestyle [53]. Though in this
option, individual constituents may be the key to altering
exposure patterns, a role is also foreseen for policy mak-
ers. Through informing and sensitizing the general audi-
ence, policy makers and risk managers can have an
important impact on the exposure profiles. Recently, the
Flemish Government started a campaign to collect previ-
ously banned pesticides such as DDT. While these com-
pounds are banned in Flanders since 1974, the Flemish
HBM program still detected elevated DDE-concentrations
in rural areas in Flanders. With exposure assumed to be
mainly due to individual behavior of constituents, the
government used HBM data to inform and sensitize theEnvironmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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general audience and to adapt environment and health
policies.
Finally, a third option concludes that no definitive verdict
can be made on the potential source of exposure, in which
case more research will be necessary.
Very often, there are considerable data gaps in the pres-
ence of detailed, relevant, and up to data toxicological
data. Paustenbach and Galbraith [9] argue that for most of
the > 200 chemicals monitored by the CDC and other
organizations, relating chemical exposure to measurable
health risks is problematic, and more research is essential
to properly inform the public. As an answer to this general
lack of reliable toxicity data, the European Commission
has recently approved the REACH legislation (Registra-
tion, Evaluation, and Authorisation of Chemicals) [34].
In this last case, when more research is needed to make a
well-balanced proposal towards policy makers and risk
managers, going through the four questions process will
allow the identification of data gaps, which in itself
already allows sound advice to be given towards future
research and policy efforts.
Translating HBM information into risk management and
policy making options (step 4) is not a straightforward
procedure. While the Expert Panel described under step 2
can be a multinational consortium of toxicologists, trans-
lating HBM information into risk management requires a
multi-disciplinary approach and is mostly region- or
nation-specific. Therefore in order to provide expert judg-
ment for step 4, a multidisciplinary Stakeholder Task
Force is proposed. The Stakeholder Task Force needs to
evaluate the evaluations and arguments of the Expert
Panel, and also takes into account political and socio-eco-
nomic arguments in a weight-of-evidence approach. It is
essential that the Stakeholder Task Force can assimilate
the mainly scientific advice of the Expert Panel, and com-
bine it with other issues such as general well-being of the
population, differences in susceptibility of sub-popula-
tions or specific windows of vulnerability, policy priori-
ties, past actions, financial and political possibilities and
public concern. The Stakeholder Task Force therefore
should not merely consist of medical and toxicological
scientists, but should also contain administrators, policy
makers, social scientists, representatives of Non-Govern-
mental Organizations etc. They will need to face the task
of balancing different lines of evidence, weigh them, and
integrate them all into one recommendation that is suita-
ble for policy support and risk management.
Risk reduction strategies
Eventually, the four-step procedure outlined above culmi-
nates into the formulation of one or more proposals to
risk managers and policy makers to control the risk of the
environmental stressors under consideration. A number
of risk reduction strategies are possible, and are discussed
in more detail below:
No immediate action needed: obviously, the outcome of
the four-step procedure may be that based on the current
knowledge on the link between environment, dose and
health, taking into account the appropriate safety factors
and the precautionary principles, no immediate threat of
environmental pollutants for human health is expected. It
remains important however to clearly document and
communicate the scientific, socio-economic and political
elements in the decision making process, because this
might be useful for later repeated risk assessments or the
evaluation of future additional or conflicting informa-
tion;
Awareness raising: While a large portion of the general
population often is aware of the threat of major environ-
mental stressors such as heavy metals, PCBs or dioxins,
there often is only limited awareness among the general
public on potential threats of many ubiquitous substances
that have attracted little or no media attention. Further-
more, media attention may be biased towards alarming
messages on the presence of chemicals in the environ-
ment. Scientists, policy makers and stakeholders should
develop clear messages on the presence of chemicals in
the environment, disseminate objective, unbiased and
detailed knowledge on potential exposure routes, health
effects and risks and propose simple yet efficient guide-
lines for the general audience to control their own expo-
sure and health risks. A number of studies have illustrated
how HBM can be effective in creating better knowledge on
exposure routes of contaminants, and hence the possibil-
ity to use this information to promote alternative lifestyles
or to change individual behavior. For example, the nega-
tive effect of fish consumption on the methylmercury
body burden and related health effects is well supported
by HBM data, especially for pregnant women and small
children [54-56]. However, fish consumption also has a
number of positive effects because of its nutritional com-
position, such as the effects of omega-3 fatty acids on the
quality of a pregnancy and the neurodevelopment of the
infant [57,58]. By integrating all this knowledge, creating
awareness in the form of advice on fish consumption pat-
terns can maximize the nutritional input from fish while
minimizing the detrimental effects of pollutants [55].
Based on this HBM-driven knowledge, several govern-
ment agencies globally recommend for pregnant women,
women of childbearing age, and children under 15
[59,60], among others:
 To mainly eat those fish species that have naturally low
mercury levels;Environmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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 To limit or ban the consumption of fresh shark, sword-
fish, or tuna;
 To check local advisories on locally caught fish, e.g. by
sports anglers
Controlling substance exposure: Raising awareness may
be an efficient way to control exposure and hence risk of
hazardous exposure, but remains a voluntary action by
individual concerned citizens rather than a harmonized
action by policy makers to protect broader groups of citi-
zens. Mainly by using legislative tools, policy makers can
better control the exposure of the broad public to poten-
tial health risks of environmental contaminants, if the
need occurs. Rather than simply banning substances (see
further), restricting the use of products under certain con-
ditions may be an efficient controlling mechanism to
limit the exposure of target populations or to limit general
exposure. A textbook example to illustrate how "control-
ling substance exposure" can be a policy strategy is
tobacco legislation in response to exposure to environ-
mental (or second-hand) tobacco smoke (ETS). As has
been illustrated many times, ETS can be biomonitored by
measuring cotinin levels in urine, which serves as a
biomarker for ETS-related health effects [61,62]. Accord-
ing to Wikipedia, the only country in the world to ban
both the selling and smoking of tobacco products is Bhu-
tan. For all other nations, smoking is not banned, but
active smoking is mainly discouraged (placing it more in
the "awareness raising" category of risk reduction
options) and policy actions are undertaken to control
exposure of non-smokers to second-hand smoke. In 2002,
the European Council adopted the Council Recommen-
dation on the prevention of smoking and on initiatives to
improve tobacco control. In this recommendation, it is
specifically mentioned that Member States should aim to
protect smokers and non-smokers from ETS, given the
health risks associated with passive smoking [39]. Many
European Member States have accordingly developed an
anti-smoking legislation, aimed at maximally reducing
the exposure to ETS for non-smokers. Recent evaluations
of national and statewide anti-smoking legislation, both
in the workplace and other areas, shows that such legisla-
tion results in a significant reduction of exposure, as well
as general improvements in respiratory and cardiac health
[63,64];
Banning substances: Banning substances is without any
doubt the most effective, yet also the most restrictive and
invasive policy action available. Banning substances can
be enforced by policy makers by ruling out the use of com-
pounds, or may be voluntarily administered by industry
through any form of pressure from policy makers or the
general audience, promoting the use of alternatives, or
simply by appealing to the good sense of any sector of
daily life responsible for emission of the substance. On
May 17th 2004, the Stockholm Convention on Persistent
Organic Pollutants (POPs) entered into force. The Con-
vention contains obligations on elimination and restric-
tion of a number of chemicals that are a matter of concern
due to their ubiquitous occurrence, persistence, bioaccu-
mulation and potential health effects on nature and
humans. While the list of chemicals identified as POPs
was mainly developed based on ecological monitoring
data instead of HBM data, HBM monitoring programs
have proven extremely useful to evaluate the efficiency of
the Stockholm convention and to monitor the decrease of
POPs in the general population [65,66]. Also, HBM sur-
vey programs are aimed at identifying new and emerging
POPs that may pose a threat on human health and for
which legislative action may be undertaken, as is the case
for among others brominated flame retardants [67,68].
Also industry can decide to phase-out chemicals which are
suspected to pose a threat on environmental and public
health, as was done for perfluorooctanyl sulfonate by 3 M
in the year 2000 [69,70].
Increased monitoring efforts: while this strategy can
overlap with "Further research" as a risk reduction strategy
(see further), increased monitoring efforts does not aim at
improving knowledge on the link between exposure and
health effects, but merely aims at closely monitoring tem-
poral or spatial trends of exposure or the development of
health effects. Especially for biomarkers with a relatively
short half-life, extreme biomarker values may be due to
special, temporary circumstances and may not reflect the
overall average exposure of constituents. Hence, increased
monitoring efforts, including repeated sampling of per-
sons with high exposure or extension of expanded sam-
pling programs to include more participants (e.g. to better
identify or validate hot-spot exposure) may be a relevant
policy option. For example, in the case of chromium bio-
monitoring for occupational exposure, an expert panel
suggested that a second or if necessary, a third spot (or 24-
hour) urine sample was needed before it could be con-
cluded that a person may be routinely overexposed [71].
For short-lived chemicals such as volatile organic com-
pounds or agricultural pesticides, peak exposure may be
due to infrequent exposure episodes and hence not repre-
sentative for average exposure. Repeated sampling of
high-exposure subjects provides more insight on the true
nature of these high-exposure episodes [72]. Increased
HBM efforts may also prove useful to better identify and
delineate areas of high exposure, so-called hot-spots.
Additional sampling may provide further information on
the specific cause of exposure, and increasing the array of
biomarkers measured may further clarify the link between
exposure, dose, and response [73,74].Environmental Health 2008, 7(Suppl 1):S2 http://www.ehjournal.net/content/7/S1/S2
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Proxy monitoring: while it is the intention of the steps
outlined in the current document to convert HBM data
into risk management and policy making options, the
most efficient way of controlling human dose may not be
by controlling human exposure, but by monitoring and
controlling a specific, main, exposure route and setting
limits for a proxy. This approach may be seen as a combi-
nation of awareness raising, controlling substance expo-
sure and increased monitoring efforts, but generally
involves ecosurveillance (or ecological biomonitoring)
instead of human biomonitoring. For a number of well-
studied chemicals such as cadmium or methylmercury,
there are well-defined exposure sources that have a major
contribution to the total dose. If more detailed informa-
tion is needed on the spatial or temporal evolution of
these compounds, an ecological biomonitoring network
may be better suited to gather this information than a
HBM network. Using animals or plants as a proxy for
human exposure can alleviate some of the more troubling
features of HBM, such as ethical issues, selecting repre-
sentative subpopulations, correcting for confounding fac-
tors or statistical power requirements. For example, the
use of lichens for monitoring of PCDD/Fs [75] or mosses
for heavy metal monitoring [76] are documented in liter-
ature. HBM surveys have extensively documented that fish
and seafood are a major source of methylmercury uptake
in humans [16,17]. Hence, improved mercury monitoring
may benefit from more detailed information on methyl-
mercury content in seafood rather than providing addi-
tional data in human tissues, certainly if this type of data
is directly fed into other policy options for risk reduction
such as "controlling substance exposure" or "raising
awareness" [77,78]. It needs to be stressed however that
the use of proxy monitoring as a substitute for HBM is
only valid if uptake routes are well understood. As already
mentioned earlier, ecosurveillance data may in any cir-
cumstance be useful for the identification of potential
(local) sources (step 3).
Further research: the absence of conclusive epidemiolog-
ical evidence of the causal link between environmental
stressors and health effects should not be a final argument
to conclude that there is no health damage and hence pre-
ventive measures are unnecessary [53,79]. The limitations
of epidemiological analysis and the uncertainty towards
potential long-term, global health impairment have led to
an increased acceptance and application of the precau-
tionary principle. While environmental damage should
be anticipated and prevented in the face of uncertainty by
avoiding potentially damaging activities whenever possi-
ble, the precautionary principle should not be used as an
endpoint of any assessment, but as a means to identify
areas of high uncertainty, and thus areas in need of further
research. In the past, the lack of high-quality toxicological
data with clear dose-response relationships has frequently
limited the efficiency of risk assessments, a situation that
should improve drastically in the future with the REACH
legislation coming into action [34]. However, also in
other areas, further research efforts may substantially
improve the relevance of risk assessments and reduce the
level of uncertainty associated with them. Going through
the higher identified four-step process will identify areas
of high uncertainty, and will trigger potential new
research topics.
Conclusion
The establishment of a European Network on HBM will
open new and exciting opportunities towards the collec-
tion of harmonized, comparable, high-quality data on the
exposure and effects of environmental contaminants in
humans. These data may provide relevant and useful
information for risk managers and policy makers, in terms
of developing, adapting and evaluating environmental
policies. However, a framework is needed to put HBM
data in perspective and to propose relevant policy adjust-
ments.
This paper outlines a hierarchic approach, based on the
stepwise formulation of 4 subsequent steps that will even-
tually lead to the formulation of a variety of policy rele-
vant risk reduction options. Although the usefulness of
this approach still needs to be tested, and potential fine-
tuning of the procedure may be necessary, approaching
the policy implications of HBM in an objective framework
will prove to be essential.
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